FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsAytu Biopharma
FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.
High risk -
DrugsAytu Biopharma
FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.
High risk -
DrugsJulyMD
FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.
High risk -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsHello Cake, Inc. dba Hello Cake
FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
Medium -
DrugsBiopreventative Company LLC dba Biopreventative
FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.
Low -
DrugsSprout Health Partners LLC dba Sprout Health
FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
Low -
DrugsMaster Pharmaceuticals Group
FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
High risk -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsHealBerry
FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
Medium -
DrugsReset IV, LLC dba Reset IV
FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
Medium -
DrugsYangzhou Yulou Paper Products Co., Ltd.
FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
High risk -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low -
DrugsBioverse, Inc. dba Bioverse
FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
Low -
DrugsSimpleRx
FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.
High risk -
DrugsElevate Your Wellness LLC, dba Elevated
FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
Low -
DrugsCosmo Medical Spa dba Cosmo Med Spa
FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
Medium -
DrugsEvoLife Wellness
FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.
Medium -
DrugseDrugstore
FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).
High risk -
DrugsNuvo Life Health Inc. dba Nuvo Life Health
FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.
Medium -
DrugsSemaBio
FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.
Low -
Drugsdirectmeds.com, Inc. dba DirectMeds
FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
High risk -
DrugsHims & Hers Health, Inc. dba Hims
FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsMane & Steel, LLC. dba Mane & Steel
FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
Low -
DrugsLumimeds
FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsCanada Med Stop
Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.
Medium -
DrugsAll American Wellness
FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.
Low -
DrugsHealthy Male
FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.
Low -
DrugsIntimate Rose
FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.
High risk -
DrugsInvigorate Med Spa
Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.
Low -
DrugsDr. Gater’s Weight Loss & Wellness
Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.
Medium -
DrugsRemedy Meds
FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.
Low -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsFancy Meds, LLC dba Fancy Meds
FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.
Low -
DrugsMatthew Stern, CEO MyStart Health LLC.
FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
Low -
DrugsAlora Pharmaceuticals
FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.
Low -
DrugsElite Health Center
FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsHealthon Inc. dba Healthon
FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
High risk -
DrugsNovo Nordisk Inc.
FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
DrugsShirish M. Gadgeel, M.D.
Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.
High risk -
DrugsHikal Limited
FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.
High risk